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Introduction
Bladder cancer (BCa) is the second most common tumor 
of the urogenital system following prostate cancer and the 
7th and the 11th most frequent diagnosed cancer in men and 
women, respectively. Overall, 75% of newly diagnosed BCa 
are non-muscle invasive (1), which is a disease burdened by 
recurrence in 60–80% of cases and progression in 10–30% 
of cases, depending on the tumor stage (2,3). Several 
risk-classification systems were developed to facilitate 
patients’ management, and they usually include clinical 
and pathological characteristic which influence patients’ 
prognosis. During the last ten years, the presence of 
histological variants in BCa became increasingly important 
and several studies were performed especially on patients 
treated with radical cystectomy (RC), to assess its role 
in muscle-invasive BCa: all of them found histological 
variants related to worse survival outcomes (4). The role 
of histological variants in non-muscle invasive tumors was 
less studied but is equally important: understanding the 
role of variant histology in these types of tumors has a 
significance to assess individual management for avoiding 
undertreatment and progression. For these reasons, our 
review is focused on the role of variant histology in non-
muscle invasive BCa.
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Evidence acquisition
A non-systematic Medline/PubMed literature search was 
done. The following items and combinations were searched 
“bladder cancer”, “bladder tumor”, “non-muscle invasive 
bladder cancer”, “NMIBC”, “histological variants” and 
“high risk urothelial cancer”. Meta-analysis, original articles 
and reviews in English language were selected.
Classification of histological variants
The prognostic importance of variant histology in BCa was 
underlined by the World Health Organization (WHO), 
which included the category of “invasive urothelial 
carcinoma with divergent differentiation”, defined as 
urothelial cancer with presence of other morphologies, 
in the 2016 classifications (5). This classification includes 
“urothelial” and “nonurothelial” variants distinguished on 
the basis of pathological morphological evaluation.
Non-urothelial variants include, first of all, the 
squamous cell carcinoma which is frequent especially in 
middle eastern countries (about 30% of all BCa cases) 
because of the diffusion of Bilharzia infection in these 
areas (6). Microscopically is characterized by the presence 
of squamous pearls, intercellular bridges and keratohyalin 
granules (7). Macroscopically are usually monofocal tumors 
with big dimension, associated with leucoplakia and mainly 
located in the trigone (8,9). The glandular variant is the 
second most common nonurothelial histological variant 
(about 18% of muscle-invasive BCa) (10) and includes four 
subtype of tumors (enteric adenocarcinoma, mucinous 
adenocarcinoma, mixed adenoma, and villous adenoma) (11). 
Also the neuroendocrine variant is divided into four 
subgroups (small cell, large cell, well differentiated, and 
paraganglioma): of them, the small cell one, is the most 
frequent but is anyhow rare and represents about 1% only 
of all BCa cases (12).
Main urothelial variants include sarcomatoid, which 
has a prevalence of 0.3–0.6% (13,14), of all bladder 
tumors. At macroscopic evaluation usually occurs with a 
polypoid shape with haemorrhagic or necrotic areas (15). 
The micropapillary variant is included in this classification 
and has a prevalence of about 0.6–2.0% of all BCa (16): 
microscopically is characterized by small nests and 
aggregates of tumor cells within lacunae without vascular 
cores. The plasmacitoid variant is rare and very aggressive 
and in majority of cases occurs at presentation as 
extravescical disease with distant metastasis (17). Similarly 
to plasmacitoid variant, the nested is usually associated with 
poor survival outcomes (18). It is characterized by irregular 
and confluent small nests and abortive tubules composed 
of urothelial cells infiltrating the lamina propria or the 
muscularis, usually without surface involvement (19,20).
Accuracy of TURBT
The diagnosis of histological variants at transurethral 
resection of bladder (TUR), present several difficulties, 
probably related to the small amount of tissue obtained with 
the endoscopic resection and to the presence of artifacts 
caused by cut and the coagulation. The accuracy of TUR 
in the evaluation of presence and type of variant histology 
has been analyzed just in a few studies, which reported 
discordant results. Moschini et al. (21) using Cohen kappa 
coefficient to evaluate agreement between findings at 
TUR and RC, found a poor agreement between the two 
specimens. In particular the concordance depended on 
the type of variant histology and was low in general and 
micropapillary variant, and high for sarcomatoid, small 
cell, and squamous variants. Similar result was shown in 
a multicenter study by Cai et al. (22) who reported a lack 
of agreement for uncommon variants between TUR and 
RC in the entire population (P<0.001). However, Abufaraj 
et al. (23), reported a high concordance rate between the 
two specimens (about 84%), with a TUR’s specificity of 
99% and negative predictive value (NPV) of 83%. Abd el-
Latif et al. (24) found a sensitivity of 39% for predicting 
variant morphology at TUR specimen, but this rate was 
variable according different subtype of histological variants. 
The discordance between the results reported in literature 
is probably due to the differences in collection and analyses 
of pathological samples. These results underline the 
importance of the methodology of resection which, when 
possible, should include “en bloc resection” and muscularis 
in the sample (13).
Treatment of non-muscle invasive histological 
variants
Intravesical therapy
In general, BCa with variant histology is considered as 
an aggressive disease and early RC should be proposed in 
majority of cases of non-muscle invasive BCa. However, 
Bacillus of Calmette-Guerin (BCG) can be safely performed 
in very selected cases. The nested variant in majority of cases 
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appears as a muscle-invasive disease (70% of cases) (25). 
Linder et al. (25), after matching for T stage, reported no 
difference in survival outcomes between nested variant and 
pure urothelial carcinoma. Similar result were found for 
patients with glandular differentiation and after adjusting 
for stage and percentage of the variant were found to 
have similar survival outcomes compared to patients with 
pure urothelial carcinoma (26). Glandular variant has 
been evaluated in a study by Miller and Epstein (27) who 
demonstrated that six patients with glandular variant where 
successfully treated with BCG (27).
Early cystectomy
Early cystectomy should be recommended in several cases of 
non-muscle invasive BCa with variant histology (28). This 
treatment should be proposed first of all, in squamous cell 
carcinoma even if T1 diseases are rare (19). The squamous 
carcinoma, therefore, was reported as significantly associated 
with recurrence and cancer specific mortality in patients with 
T1 BCa not treated with early RC (29,30). Patients with 
sarcomatoid variant have poor oncological outcomes with 
worse survival and higher cancer specific mortality compared 
to patients with pure urothelial carcinoma. Moreover, it 
usually occurs as extravesical disease at RC with high rates 
of local progression and distant metastasis (14,31-33). 
No study regarding effectiveness of intravesical treatment 
in this variant has been published, but according the 
results of before mentioned study an early RC should be 
proposed to these patients. Same suggestion is reserved 
for micropapillary carcinoma: therefore Kamat et al. (34) 
reported high rates of BCG-failure (67%) with 22% of 
patients who developed distant metastasis and no patients 
treated with delayed RC was alive at 10 years (35). When 
analyses was focused on non-muscle invasive BCa they 
reported worse survival outcomes for patients treated with 
BCG compared to those treated immediate RC (36). Similar 
results were reported by Ghoneim et al. (37) who analyzed 
data of ten patients with micropapillary BCa. Seven patients 
were treated with BCG, all had a recurrence and 6 of them 
had a pT3 disease at RC with node involvement (37). 
A recent meta-analysis analyzed patients with T1 
micropapillary BCa and reported a 5-year cancer specific 
survival rate between 60% and 85% in patients treated with 
resection plus BCG instillation and from 81% to 100% 
in patients treated with early RC (38). Since plasmacitoid 
variant is very aggressive and chemosensitive (39) an 
early RC plus neoadjuvant/adjuvant therapy should be 
proposed (40). Same suggestion for the small cell carcinoma 
in which RC should be proposed also for non-muscle 
invasive disease.
Conclusions
The diagnosis of histological variants at TUR specimen 
is difficult, probably due to the small account of tissue 
obtained through endoscopic resection and presence of 
artifacts related to coagulation and cut. The presence of 
variant histology is usually associated with advanced diseases 
and poor oncological outcomes. In the majority of case of 
variant histology and in particular in case of sarcomatoid, 
plasmacitoid, micropapillary and neuroendocrine non-
muscle invasive tumors, immediate RC should be suggested. 
In case of glandular or nested differentiation BCG 
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